Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Clinical trial NCT05683834 · COMPLETED

Trial details

NCT number: NCT05683834
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Epstein-Barr Virus Infection Infectious Mononucleosis Herpesvirus

Start date: 2023-09-22
Primary completion: 2026-04-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.